About
Biologist by training; received his PhD in Immunology in 1992. When at Georg August University in Göttingen, he co-developed the key in-vitro differentiation protocol for dendritic cells. In 1990, he joined Scolaro and contributed to the early investigations into therapeutic intracellular targeting of HIV-infected APCs with sense/antisense to the tat gene. Subsequently, Ruppert joined the publicly listed biotech company Cytel Corp. in San Diego, California, as a Research Scientist for three years in drug development utilizing antigen presentation technologies. After three years in a position in Marketing with the German subsidiary of a large US corporation, ICN Biomedicals, he became a partner for eight years with the Venture Capital firm, Heidelberg Innovation, as an Investment Manager specializing in financing, developing, and selling of biotechnology and pharmaceutical start-up companies. He currently holds the position of Director International Sales & Marketing with a med
Position in the VCSift Database
- • 1 investors hold the Co Founder & Chief Consultant Investor Relations role in VCSift. Jorg Ruppert is one of them.
- • 381 investors are based in Frankfurt, Hessen, Germany.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Frankfurt, Germany
Contact Information
Find more investors like Jorg
Search Investors